---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-104076"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2026-09-28T20:31:05+00:00"
generated_at: "2026-10-12T13:36:52.495145+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Unicycive Therapeutics faces securities class action over oxylanthanum carbonate NDA statements

## Summary
- Securities class action filed Sept 3, 2026 in the U.S. District Court for the Northern District of California against Unicycive and certain officers.
- Lawsuit alleges federal securities law violations tied to public statements about the new drug application for oxylanthanum carbonate phosphate binder.
- The drug targets hyperphosphatemia in chronic kidney disease patients on dialysis; Unicycive calls the claims meritless and vows vigorous defense.
- Report signed Sept 28, 2026 by CFO John Townsend; UNCY common stock trades on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001213900-26-104076
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2026-09-28T20:31:05+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390026104076/0001213900-26-104076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390026104076/ea0306890-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-104076
- JSON: https://secwatch.observer/filing/0001213900-26-104076.json
- Plain text: https://secwatch.observer/filing/0001213900-26-104076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.